Royal Bank of Scotland Revises Bid for ABN Amro

Tishman Speyer Properties and Lehman Brothers are near a deal to purchase Archstone-Smith, and more stocks in the news

A consortium of banks led by Royal Bank of Scotland says it will go forward with a $95.61 billion takeover bid for ABN Amro Holding (ABN), according to the Wall Street Journal. This is above the bid from Barclays (BCS).

Tishman Speyer Properties and Lehman Brothers (LEH) are near a deal to purchase Archstone-Smith (ASN), a leading apartment real estate investment trust, for more than $12 billion, according to the Wall Street Journal.

Avaya Inc. (AV) is in talks with private equity to sell part or all of the company, signaling a possible new round of industry deals, according to the Wall Street Journal.

Alcan (AL) shares were higher in premarket trading after unconfirmed report in the Globe and Mail said Norsk Hydro ASA is preparing an offer for Alcan in excess of $30 billion, topping Alcoa's (AA) offer of $27.8 billion. S&P reiterates hold on Alcan shares.

Washington Group (WNG) agrees to be acquired by URS Corp. (URS) in a $2.6 billion deal. Terms: $43.80 in cash, 0.772 URS share for each WNG share.

The Federal Trade Commission has opened an antitrust investigation into Google's (GOOG) proposed $3.1 billion acquisition of DoubleClick, according to news reports.

Tribune (TRB) and Gannett (GCI) terminate a deal under which Gannett was to purchase Tribune's Southern Connecticut Newspapers, The Advocate and Greenwich Times. Tribune says it will immediately begin soliciting offers for the newspapers.

Pogo Producing (PPP) says it agrees to sell its Northrock Resources unit to Abu Dhabi National Energy Company PJSC for $2 billion in cash.

Advanced Medical Optics (EYE) is recalling its Complete MoisturePlus contact lens solution in response to information received from U.S. Centers for Disease Control and Prevention (CDC) regarding eye infections.

Integrated BioPharma (INBP) cut $68-$70 million fourth-quarter revenue forecast to $64-$66 million due to decreases in consumer spending forecasts by major chain retailers that are also company's Neutraceutical customers.

Before it's here, it's on the Bloomberg Terminal.